» Articles » PMID: 33937970

Serum Levels of MiR-146a in Patients with Psoriasis

Overview
Journal Mol Diagn Ther
Date 2021 May 3
PMID 33937970
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Psoriasis is an immune-mediated disease with interactions between genetic and environmental factors. An increasing number of studies are demonstrating the importance of microRNAs (miRNAs) in the pathogenesis of psoriasis. miR-146a, a dominant negative regulator of inflammation, has been consistently reported as overexpressed in the skin and peripheral blood mononuclear cells (PBMCs) of patients with psoriasis. Expression and/or function of this miRNA is highly influenced by genetic variations, some of which have already been associated with susceptibility to psoriasis.

Objective: We sought to study the importance of miR-146a in patients with moderate-to-severe psoriasis and to understand the impact of rs57095329 and rs2910164 polymorphisms in a psoriatic Portuguese population.

Methods: miR-146a circulating levels were quantified using molecular biology techniques in 99 patients with moderate-to-severe psoriasis (35 female, 64 male; age 47.4 ± 10.9 years) and 78 healthy individuals (52 female, 26 male; age 42.4 ± 10.1 years). miRNA expression was correlated with clinicopathological features as well as with genetic data such as the presence of human leukocyte antigen (HLA)-C*0602 allele and two miR-146a polymorphisms (rs2910164 and rs57095329).

Results: miR-146a serum levels were 3.7-fold higher in patients with psoriasis than in controls (p < 0.0001, area under the curve [AUC] 0.75; 95% confidence interval [CI] 0.66-0.83). Of note, miR-146a circulating levels positively correlated with Psoriasis Area and Severity Index (p < 0.05) and body surface area (p < 0.05) indexes. No variations in miR-146a levels were observed with rs2910164 and rs57095329 genotypes.

Conclusion: Circulating miR-146a levels were upregulated in patients with psoriasis, especially in those with active disease. To the best of our knowledge, this is the largest study with a homogenous psoriasis population, and our data could shed light on the pathogenesis of psoriasis, paving the way for new avenues for disease treatment.

Citing Articles

Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs.

Teo L, Juantuah-Kusi N, Subramanian G, Sampath P Noncoding RNA. 2025; 11(1).

PMID: 39997616 PMC: 11858470. DOI: 10.3390/ncrna11010016.


A Review of MicroRNAs and lncRNAs in Atherosclerosis as Well as Some Major Inflammatory Conditions Affecting Atherosclerosis.

Letonja J, Petrovic D Biomedicines. 2024; 12(6).

PMID: 38927529 PMC: 11201627. DOI: 10.3390/biomedicines12061322.


MicroRNA-146a Signature in Psoriasis: A Systematic Review and Meta-Analysis.

Ho P, Huang Y Mol Diagn Ther. 2024; 28(4):379-388.

PMID: 38773009 DOI: 10.1007/s40291-024-00714-0.


Selected miRNA and Psoriasis-Cardiovascular Disease (CVD)-Overweight/Obesity Network-A Pilot Study.

Michalak-Stoma A, Walczak K, Adamczyk M, Kowal M, Krasowska D Int J Mol Sci. 2023; 24(18).

PMID: 37762217 PMC: 10530775. DOI: 10.3390/ijms241813916.


The Essential Role of microRNAs in Inflammatory and Autoimmune Skin Diseases-A Review.

Dopytalska K, Czaplicka A, Szymanska E, Walecka I Int J Mol Sci. 2023; 24(11).

PMID: 37298095 PMC: 10253000. DOI: 10.3390/ijms24119130.


References
1.
Christophers E . Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001; 26(4):314-20. DOI: 10.1046/j.1365-2230.2001.00832.x. View

2.
Kaushik S, Lebwohl M . Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2018; 80(1):27-40. DOI: 10.1016/j.jaad.2018.06.057. View

3.
Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R . Psoriasis causes significant economic burden to patients. Dermatol Ther (Heidelb). 2014; 4(1):115-24. PMC: 4065269. DOI: 10.1007/s13555-014-0053-2. View

4.
Hawkes J, Chan T, Krueger J . Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017; 140(3):645-653. PMC: 5600287. DOI: 10.1016/j.jaci.2017.07.004. View

5.
Capon F . The Genetic Basis of Psoriasis. Int J Mol Sci. 2017; 18(12). PMC: 5751129. DOI: 10.3390/ijms18122526. View